American biotechnology company that rears gene-edited pigs for organ transplantation (xenotransplantation). Co-founded by George Church, a biologist at Harvard University. Its boss is Mike Curtis.
eGenesis provided the pig kidney transplanted into Tim Andrews at Massachusetts General Hospital in January 2025, which lasted 271 days—a record. In September 2025 the FDA gave eGenesis permission to begin full-scale clinical trials of pig kidneys. The company is collaborating with Eledon, a firm testing a new anti-rejection drug called tegoprubart that it hopes will have fewer side-effects than existing immunosuppressants.
eGenesis also has approval to trial a pig-liver perfusion system, using an organ-preserving device from OrganOx, a University of Oxford spin-out.
Two wrongs don't make a right, but they make a good excuse.